ArticleInterdisciplinary sciences, computational life sciences2026
A Hypergraph-Based Model for Predicting Potential Drug Combinations in Cancer Therapy.
Article in Interdisciplinary sciences, computational life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Finding effective drug combinations is a pivotal strategy for enhancing therapeutic efficacy and overcoming drug resistance in complex diseases like cancer. While computational methods have accelerated this discovery, most existing models are confined to predicting pairwise interactions, failing to capture the complex, higher-order synergies inherent in multi-drug regimens. To bridge this critical gap, we introduce an enhanced hypergraph random walk (EHRW) model uniquely designed to predict effective drug combinations. Our framework naturally represents multi-drug relationships using hypergraphs and leverages network topology to predict combination efficacy. Recognizing that network structure alone may not fully capture the intricate biological properties of drugs, we further propose a robust post-processing strategy that refines initial predictions by integrating auxiliary drug features. This method, which uses chemical similarity derived from SMILES fingerprints, serves as a powerful validation layer, significantly boosting the model's predictive accuracy. We demonstrate the superior performance of our enhanced EHRW model through rigorous validation on two major cancer datasets (lung and breast cancer). Our results show that the chemical similarity-based post-processing strategy outperforms the original model and several contemporary baselines. Importantly, our model extends beyond binary prediction by introducing a straightforward scoring method for three-drug combinations, which averages the predicted scores of their constituent binary pairs and provides a practical pathway for evaluating higher-order therapies. The enhanced EHRW model offers a flexible, accurate, and scalable computational tool, paving the way for more precise discovery of effective multi-drug regimens.
Indexed as
Identifiers
41118051What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.